When more than 1 drug exists within the same LOE, and there are no comparative data, then the drugs are listed alphabetically. ACT indicates activated clotting time; COR, Class of Recommendation; GPI, glycoprotein IIb/IIIa inhibitor; IV, intravenous; LOE, Level of Evidence; N/A, not applicable; PCI, percutaneous coronary intervention; SC, subcutaneous; and UFH, unfractionated heparin. Modified from Levine et al.26 studies of ticagrelor did not translate to a lower risk of bleed- ing or lessen the need for transfusion compared with clopido- grel when CABG was performed early (ie, <5 days) after drug See Online Data Supplements 21 and 22 for more informa- tion on myocardial revascularization. 6. Late Hospital Care, Hospital Discharge, And Posthospital Discharge Care 6.1. General Principles (Cardioprotective Therapy and Symptom Management) The goals of therapy after NSTE-ACS are to restore the patient to normal activities to the extent possible and to use the acute event to re-evaluate the plan of care, particularly lifestyle and risk factor modification. Aggressive risk factor modifications that can prolong survival should be the main goal of long-term management of patients with stable CAD. Patients presenting with NSTE-ACS represent a high-risk cohort in whom sec- ondary cardiovascular disease prevention is likely to be par- ticularly effective (Table 10). Clinicians have an opportunity to provide evidence-based care to this high-risk cohort and to aggressively treat the underlying atherosclerotic process through lifestyle modification and effective pharmacological In most cases, the inpatient anti-ischemic medi- cal regimen should be continued after discharge, and the anti- platelet/anticoagulant medications should be changed to an outpatient regimen. 